Neurotrophins and their receptors play a key role in neurogenesis and survival. However, we and others have recently obtained evidence for a potential involvement of this receptor system in leukemia. To investigate mechanisms underlying the leukemogenic potential of activated neurotrophin receptor signaling, we analyzed in vivo leukemogenesis mediated by DTrkA, a mutant of TRKA (tropomyosin-related kinase A) isolated from a patient with acute myeloid leukemia (AML). Retroviral expression of DTrkA in myeloid 32D cells induced AML in syngeneic C3H/Hej mice (n ¼ 11/11, latency B4 weeks). C57Bl/6J mice transplanted with DTrkA-transduced primary lineage negative (Lin À ) bone marrow cells died of a transient polyclonal AML (n ¼ 7/15, latency of o12 days). Serial transplantation of AML cells did not re-induce this disease but rather acute lymphoblastic leukemia (ALL, latency 478 days). All primary recipients surviving the early AML developed clonal ALL or myeloid leukemia (latency 472 days) that required additional genetic lesions. PI3K and mTOR-raptor were identified as the crucial mediators of leukemic transformation, whereas STAT and MAP kinase signaling pathways were not activated. Thus, our findings reveal potent and unique transforming properties of altered neurotrophin receptor signaling in leukemogenesis, and encourage further analyses of neurotrophin receptors and downstream signaling events in hematological malignancies.
Introduction
Current concepts of leukemogenesis postulate a collaboration of 'class I' mutations that result in constitutively activated proteintyrosine kinases (PTKs) with 'class II' mutations of transcription factors such as AML/Runx or ETS proteins. In this scenario, class I mutations (for example BCR/ABL, TEL/PDGFbR) promote proliferation but do not inhibit differentiation, while the reverse is true for class II mutations. 1, 2 There is now growing evidence for involvement of multiple PTK oncogenes, their immediate downstream targets, or of proteins regulating their function in hematological malignancies. 2, 3 Despite differences in structure, function and subcellular location, many of the PTK oncogenes signal through the same pathways to typically enhance proliferation and prolong viability. 3 These pathways include activation of the Ras/Raf/MAPK (mitogen-activated protein kinase), signal transducers and activators of transcription (STATs), and phosphatidylinositol 3-kinase (PI3K). The latter signals through the proteinserine/threonine kinase Akt, mammalian target of rapamycin (mTOR) and p70S6 kinase (p70S6K). 4, 5 The neurotrophins (NTs), which comprise nerve growth factor (NGF), brain-derived neurotrophic factor, NT-3, NT-4 and NT-6, play a major role in neuronal survival and maintenance. NTs are unique in using two different classes of receptors: the TRK (tropomyosin-related kinase) receptor PTK (TRKA ¼ NTRK1, TRKB ¼ NTRK2, TRKC ¼ NTRK3) and the low-affinity NGF receptor (LNGFR, also known as NGFR and p75NTR), 6 a member of the tumor necrosis factor cytokine receptor family. NT binding to TRK receptors leads to dimerization of receptors and kinase activation. LNGFR may modulate the activity of this signaling complex but is not required for its function. 6 Of note, human embryonic stem cell survival has recently been shown to be mediated through activation of TRK receptors by NTs. 7 Members of the TRK family may also play a crucial role in initiation, progression and metastasis of many tumors in humans, for instance medullary thyroid carcinoma and breast cancer. [8] [9] [10] Although TRK receptors and the respective ligands are expressed at various stages of hematopoiesis, their hematopoietic function remains largely unexplained. 11 There is now increasing evidence for involvement of TRK receptors in leukemia. Expression of TRKA mRNA was found in primary leukemic cells of 44% of patients with AML. 12 A cryptic translocation t(12;15) (p13;q25) was found in an AML patient, which resulted in a chimeric transcript TEL-TRKC. 13, 14 Furthermore, in an AML patient, a deleted form of TRKA, DTrkA, was identified, lacking 75 amino acids in the extracellular domain. 15 This deletion led to loss of the main part of the second Ig like domain, which prevents spontaneous dimerization. 16 The resulting activation of the tyrosine kinase domain and constitutive tyrosine phosphorylation of the receptor transformed fibroblasts. 15 Another study revealed the induction of TRKA and a contribution of NGF to survival signaling in human cord blood cells transduced with retroviral vectors encoding the AML1-ETO oncogene. 17 In addition, we had evidence to suggest that a cytoplasmically deleted form of LNGFR may contribute to leukemia in mice. 18 Furthermore, we observed expression of LNGFR in patients with acute leukemia (AL), preferentially in common ALL and in association with BCR/ABL. 19 Taken together, these data suggest an important role of NT-signaling in leukemogenesis.
To explore the leukemic potential and associated signal alterations induced by an activated TRK receptor, we retrovirally introduced DTrkA into murine hematopoietic cells. Our data reveal that DTrkA transforms both an immortal myeloid cell line and primary hematopoietic stem cells (HSC), eventually resulting in myeloid and/or lymphatic leukemia. Our study shows that DTrkA is not only strongly leukemogenic, but also differs from other receptor PTKs by activating PI3K-mTOR pathways without co-activating STAT and MAPK proteins. In addition, phospholipase D (PLD) played an important role in malignant transformation by DTrkA. Our data reveal an important role of altered TRK signaling in leukemogenesis, and support the evolving concept that an impaired regulation of the PI3K-mTOR pathway is strongly implicated in hematological malignancies. [20] [21] [22] This pathway could become an important target for the development of innovative strategies.
Materials and methods

Retroviral vectors and vector production
SF91.IRES-EGFP.wPRE has been described elsewhere. 23 The vector is referred to as SF91-IE. A PCR fragment containing the cDNA of DTrkA was generated and cloned into NotI site before the IRES-EGFP cassette of SF91-IE. This vector encoding DTrkA was named SF91DTrkA-IE (Figure 1a ). SF91 retroviral vector has been shown to mediate efficient transgene expression in hematopoietic cells. 23 Cell-free high-titer supernatants containing the ecotropic envelope protein were generated as previously described. 23 
Retroviral transductions, in vivo tumorigenesis assays and tumor phenotyping
Murine hematopoietic cells were transduced with ecotropic supernatants (Figure 1b) , using conditions that led to efficient gene marking with low provirus copies (o3) per cell. 23 Polyclonal cultures of retrovirally engineered 32D cells were used for in vivo tumorigenesis experiments. A total of 10 7 cells per recipient were inoculated by intravenous injection into sublethally irradiated (2.5 or 4 Gy) C3H/Hej mice. 24 Hematopoietic stem/progenitor cells (HSC/HPC)-enriched lineage negative (Lin À ) bone marrow (BM) cells were isolated from C57Bl/6J.Ly5.2 mice and transduced as previously described. 23 Gene-modified cells were transplanted by tail-vein injection into lethally irradiated syngeneic recipients (aged 8-16 weeks). Secondary transplantations were performed using single cell suspensions from selected tumor samples. To identify the target cells of malignant transformation by DTrkA, HSC populations (Lin
were sorted from BM mononuclear cells isolated from healthy C57Bl/6J.Ly5.2 mice as described, 25 26 Mice that did not develop leukemia were analyzed according to the same protocol after a maximal observation period of 37 weeks.
Leukemic cell growth in methylcellulose and liquid culture, apoptosis assay and cell cycle analysis
To analyze clonal growth, 2 Â 10 2 or 2 Â 10 3 cells per dish were plated in M3234 media (StemCell Technologies, Vancouver, Canada) in the presence of signal transduction inhibitors. The assays were plated as duplicates or quadruplicates, and colonies were counted on day 6. Inhibition of cell growth was also investigated in cell suspension culture. The cell numbers were counted 24 h after coculture of leukemic cells in the presence of inhibitors. Cell viability was analyzed using the Annexin-V assay (BD Pharmingen, Heidelberg, Germany). Cell cycle analysis was performed using bromodeoxyuridine (BrdU) flow kit that followed the manufacturer's instruction (BD Pharmingen). Inhibitors K252a, PD98059, LY294002, and rapamycin (Calbiochem, Merck, Bad Soden, Germany), wortmannin (Cell Signaling, Danvers, MA, USA) and 1-butanol were used with concentrations indicated in results.
Ligation-mediated PCR, Southern blots, northern blots, western blot analysis and electrophoretic mobility shift assays Our protocol for ligation-mediated PCR (LM-PCR) followed published conditions. 27 Genomic DNA was harvested using the QIAamp blood kit (Qiagen, Hilden, Germany). Single-cell suspensions of mouse organs prepared at necropsy were collected by centrifugation. 28 To investigate the effect of signal transduction inhibitors on activation of mTOR and its substrates, leukemic cells were cultured with pretreatment by inhibitors for 30 min or 12 h. 21 Both 32D wt (wild-type) cells and 32D cells expressing TRKA (human full-length TRKA) 15 and c-MPL (Myeloproliferative leukemia protein, thrombopoietin receptor) were used as controls for signal transduction analysis. Cell extracts were prepared following established protocols. Cell lysates were used as indicated in results. Southern, northern, and western blots, electrophoretic mobility shift assays and immunoprecipitations were performed as previously described. 18, 28 The double-stranded high-affinity sis-inducible element (hSIE) oligonucleotide was used as a probe for Stat3 binding. Antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), Cell Signaling and Biomol (Hamburg, Germany).
Chromosome preparation and spectral karyotyping analysis
Preparation of metaphase chromosomes and cytogenetic characterization using spectral karyotyping (SKY) was carried out as described. 29 A total of 10-15 metaphases per case were analyzed.
Results and discussion
DTrkA renders 32D cells leukemogenic in vivo
To explore the leukemogenic potential of a constitutively activated TRK receptor, we focused on the deletion mutant DTrkA. 15 In a previous study, overexpression of DTrkA by retroviral gene transfer resulted in the constitutive activation of intracellular signaling pathways (for example Ras) and readily transformed fibroblasts. 15 To address the in vivo leukemogenic potential of DTrkA, we first used a model based on nonleukemogenic myeloid, interleukin-3 (IL-3) dependent 32D cells (Figure 1b) . 24 Retroviral expression of DTrkA in 32D cells caused growth-factor independence in vitro, especially when being highly expressed (Supplementary data). Even without selecting for growth-factor independence in vitro, DTrkAtransduced 32D cells elicited a fatal AML in sublethally irradiated syngeneic C3H/Hej recipients (latency of about 5 weeks) (Figure 1c ). This was reproducibly observed in three independent experiments using cell populations that expressed the transgene to 3, 30 and 50%, respectively. Leukemias led to a massive enlargement of spleen and liver. Histopathology revealed extensive infiltration of blasts in the spleen, liver and BM, in some cases also in the lung, kidney and peripheral blood. Hemorrhage and thrombosis were encountered in the lungs of some cases. Expression of DTrkA in leukemic cells was confirmed by Northern blot analysis (Supplementary data). Interestingly, DTrkA was more efficient in transforming 32D cells than the dominant oncogene SV40 large T antigen (SV40LT) (latency of about 8 weeks). 24 
DTrkA transforms primary murine HSC/HPC
We next assessed the ability of DTrkA protein to transform primary murine hematopoietic cells following bone marrow transplantation (BMT). We enriched HSC/HPC of C57Bl/6J mice by depletion of lineage-antigen-expressing cells (thus obtaining Lin À cells) and cultured these under serum-free growth conditions supplemented with defined cytokines. 23 Lin À cells were transduced with SF91DTrkA-IE or control vector SF91-IE. Flow cytometric analysis of EGFP expression 2 days after transduction revealed gene transfer rates in three independent experiments in the range of 15-55% and 31-44% for SF91DTrkA-IE and SF91-IE, respectively (data not shown).
In three independent experiments, all animals (lethally irradiated C57Bl/6J, n ¼ 15) that were transplanted with Lin À cells expressing SF91DTrkA-IE developed leukemia within 124 days after BMT (Figure 1d ). Approximately half of the mice (7/ 15) developed a hyper-acute AML with a latency of o12 days ( Figure 1d ). The disease was not only more rapid than leukemia induced by retroviral transduction of BCR/ABL (reported to require generally at least 17 days), 30 but also manifested with a maturation arrest of myeloid blasts (Figure 2 ). To our knowledge, such a maturation arrest has not been observed for any other myeloid leukemia-associated oncogene alone in similar BMT models. 2, 25, 30 Remarkably, all animals surviving the early blast crisis (8/15) subsequently succumbed to lymphoblastic leukemia (ALL) or MPD-like myeloid leukemia. Interestingly, one animal (#406) presented the coexistence of both lymphoma (thymus) and myeloid leukemia (spleen, liver).
All diseased animals had a significantly enlarged spleen (360-1330 mg, mean 874 mg; control 40-154 mg, mean 90 mg) (Figures 2a and b) , and all ALL mice had a strongly enlarged thymus (up to 620 mg, control mice o20 mg) (Figure 2a ). In addition, the majority of diseased animals presented with an enlarged liver (1517-2340 mg, mean 1862 mg, control 750-1250 mg, mean 978 mg) and elevated white blood cell (WBC) counts (up to 91 Â 10 3 /ml) ( Figure 2c ). Histopathology of all diseased mice showed extensive leukemic infiltrations in analyzed organs including spleen, liver, BM, lung, kidney and thymus (only in ALL) (Figures 2d-t, and data not shown). The ALL animals also had strong infiltrations in the parasternal soft tissue (Figure 2e ), in agreement with the phenotype of lymphoblastic malignancies. Another interesting finding was meningeal infiltration of leukemic cells in all four analyzed diseased mice irrespective of the transformed lineage, that is #512 (early AML), #482 (MPD-like myeloid leukemia), #481 and #483 (both ALL). Cerebral infiltration of leukemic cells was also seen in #483 (Figures 2k and l) . Importantly, the seven animals that died early of AML showed necrotic tumor emboli in the blood vessels in lung, liver and kidney. Particularly in the lung, circulating malignant myeloid cells caused pulmonary thromboses and cellular plugs (Figures 2s and t) , demonstrating a very aggressive phenotype. Flow cytometry of single cell suspensions from the spleen, liver, thymus, BM and peripheral blood revealed that leukemic cells were transgene positive (range from 33.3 to 91.9% in the spleen). Myeloid leukemic cells expressed CD11b, Gr1 (Supplementary data), F4/80, Ter119, CD61 (data not shown), while lymphoblastic leukemic cells expressed CD44, CD25, CD4 and CD8, but in some cases not CD3 (Supplementary data).
Control mice (n ¼ 8) were transplanted with BM expressing SF91-IE. They were healthy as observed until 161 days after BMT. BM cells were taken from two animals (#416, 417) and transplanted into secondary recipients. They did not develop an obvious disease within an observation time of another year. Interestingly, SV40LT-transduced cells were far less aggressive than those expressing DTrkA, as observed in the 32D model. 24 Taken together, these data demonstrate that DTrkA is a very aggressive oncogene that transforms primary murine BM cells and induces both myeloid and lymphoblastic leukemia.
Clonality studies combined with insertion site analyses and cytogenetics reveal that DTrkA depends on additional mutations to induce lymphoblastic leukemia Using Southern blot and LM-PCR, the 'later' leukemias (mainly lymphoblastic) were found to be oligoclonal or monoclonal, while myeloid leukemias with early manifestation (#478, #479) were polyclonal (Supplementary data). Sequencing of the retroviral insertion sites revealed some interesting hits in the lymphoid leukemias (Supplementary data): one animal (#483) showed an insertion next to Bcl11a, and another (#481) insertion in the neighborhood of the highly related gene Bcl11b. Both Bcl11a and Bcl11b are required for normal lymphoid development, 31 and their deregulation has been implicated in mouse and human leukemias. 32 However, not all leukemias showed insertion sites in established proto-oncogenes (Supplementary data), suggesting that other epigenetic or genetic events were responsible for clonal dominance. We thus performed cytogenetic studies in three leukemia cases using SKY. Results were normal for an early AML (#479) and a 'later' myeloid leukemia (#482), whereas an ALL (#480) showed trisomy 15 (5/15 metaphases) (Supplementary data), a frequent chromosome aberration in murine myeloid and lymphoid leukemias. These data strongly suggest that induction of lymphoblastic leukemia following retroviral transfer of DTrkA into Lin À cells requires collaborating mutations.
Crucial role of PI3K and mTOR-raptor signaling pathways but not STAT and MAPK in DTrkA-induced leukemia By immunoprecipitation, we investigated protein expression and phosphorylation of DTrkA in leukemic samples. DTrkA was highly expressed and constitutively phosphorylated in all analyzed samples (Figure 3a) . In marked difference to wild-type TRKA, we observed extensively increased overall tyrosine phosphorylation in 32D cells by DTrkA irrespective of stimulation by IL-3 or NGF (Figure 3b) , indicating high tyrosine kinase activity. Next, we characterized the downstream events to identify the transforming cascades triggered by DTrkA. We did not observe constitutive phosphorylation of MAPK in transduced 32D cells (Figure 3c ) or leukemic cells isolated from C3H/Hej and C57Bl/6J recipients (Figure 3d ), suggesting that activation of MAPK is not necessarily required for DTrkA-induced leukemia, reminiscent of findings reported in the myeloproliferative syndrome caused by TEL -TRKC fusion protein.
14 Although STAT3 and STAT5 are activated by a broad spectrum of PTK fusions or mutations associated with hematological malignancy, for example FLT3, 33 in the present study, expression of DTrkA activated neither STAT3 (Supplementary data) nor STAT5 proteins (data not shown) in the leukemic cells, as described before in fibroblasts. 15 Similarly, STATs were not involved in leukemogenic transformation caused by TEL -TRKC. 14 This suggests that induction of hematological malignancy by NT signaling does not require activation of members of the STAT family. As PI3K is the major survival-promoting protein for neurons, 34 and PI3K and some of its downstream targets (for example Akt, mTOR) play a crucial role in oncogenic PTK signaling, 4, 5 we next characterized this pathway. Although Akt was phosphorylated after NGF stimulation in 32D cells expressing wt-TRKA, we did not observe constitutive activation of Akt in 32D cells expressing DTrkA (Figure 3e ) or in leukemic samples (Figure 3f) .
For further characterization of major pathways responsible for leukemia development by DTrkA, we investigated growth inhibition (both hematopoietic colony formation assay and liquid culture) and apoptosis induction by using different signal transduction inhibitors, including K252a, a selective inhibitor of TRK kinase, PD98059, an inhibitor of MEK (upstream activator of MAPK), LY294002 and wortmannin, selective inhibitors of PI3K. In colony assay, when leukemic cells were grown in the absence of IL-3, K252a gave rise to 450% growth inhibition, while we observed no inhibition by PD98059; 10 mM LY294002 resulted in up to 86% growth inhibition, 20 mM led to 495% killing of leukemic cells, while no growth inhibition of wild-type 32D cells was observed. Addition of IL-3 partially rescued leukemic cells from the inhibitory effect of LY294002, while no inhibition was observed for K252a and PD98059 in the presence of IL-3 ( Figure 4a ). Growth inhibition by PI3K inhibitors was further confirmed in cell suspension culture (Figure 4a ). Apoptosis analysis revealed that up to fourfold more leukemic cells underwent apoptosis 24 h after culture in the presence of LY294002 or wortmannin. We performed cell cycle analysis and found that inhibition of cell growth by LY294002 was mainly owing to arrest in G1 phase (Supplementary data). These data demonstrated that tyrosine kinase activity of DTrkA was required for leukemic transformation, and that PI3K was a crucial effector for oncogenic activity of DTrkA, while MAPK was not involved.
Although DTrkA did not constitutively activate Akt, a dosedependent growth inhibition of leukemic cells was observed in the presence of rapamycin (a specific inhibitor for mTOR) both in colony assay (up to 80% for #370 cells, Figure 4b , and up to 100% for cells isolated from the mouse #459, data not shown) and in suspension culture (up to 50%) (data not shown). About 2.5-fold more leukemic cells went to apoptosis 24 h after culture in the presence of rapamycin (Supplementary data). Cell cycle analysis suggested that the inhibition effect of rapamycin on leukemic cells was mainly owing to arrest in G1 phase of cells (Supplementary data), as previously reported. 21 The mTOR is a key regulator of growth and survival in many cell types. Its constitutive activation has been involved in the pathogenesis of various cancers. 5 The upstream effectors that activate mTOR have been extensively investigated in the past couple of years. Akt can activate mTOR either by direct phosphorylation or via inactivation of its repressor, TSC2. 5 Recent data described a regulatory mechanism of mTOR signaling involving PLD and the lipid second messenger phosphatidic acid (PA). 35, 36 Moreover, PLD has been shown to be upregulated in TRKA-expressing rat pheochromocytoma (PC12) cells after NGF-stimulation. 37, 38 Mammalian PLD activity is regulated by many factors including protein kinase C (PKC). 39 Accordingly, we observed elevated activation of PKC in DTrkA-induced leukemic cells (data not shown). To assess a role of PLD and PA in transformation by DTrkA, leukemic cells were cultured with various concentrations of 1-butanol, a primary alcohol that inhibits PLD-catalyzed PA formation. As shown in Figure 4c , exposure to 1-butanol led to a dose-dependent growth inhibition (up to 50%), suggesting a role of PLD in leukemic transformation, possibly via activation of mTOR signaling. 36 Furthermore, we performed western blot analysis to verify the inhibition effect on signal transduction molecules in cell suspension. We first investigated phosphorylation of mTOR and its downstream effectors, the best characterized of which are p70S6K and 4E-BP1 (eukaryotic translation initiation factor 4E binding protein 1). p70S6K phosphorylates the S6 protein of the 40S ribosomal subunit. As shown in Figure 4d , mTOR, 4E-BP1 and S6 protein were constitutively phosphorylated in leukemic cells. Then, we examined the effect of inhibitors on the phosphorylation of mTOR. -14) , separated on SDS-PAGE, blotted and probed with an anti-pTRKA (E-6). The blot was stripped and reprobed with the anti-TRKA (763) antibody. DTrkA was constitutively phosphorylated in all leukemic samples analyzed. Signals were stronger in samples of early AMLs (#478, #479) than in samples of leukemias with later manifestation (#480 and #482). Note that DTrkA migrated as proteins of ca. 90 Kda (major) and 110 Kda (minor). 15, 16 The disproportionate reduction of molecular weight caused by the deletion of only 75 amino acids may reflect the loss of four glycosylation sites. 45 (b) Anti-phosphotyrosine blot of total cell lysates from 32DDTrkA cells and 32DTRKA. 15 Cells were cultured in the presence of IL-3 or after starvation for 12 h (culture medium without IL-3 and FCS supplemented for 0.5% BSA) and subsequently stimulated with IL-3 or NGF. Immunoblotting was performed with monoclonal antibody 4G10 against phosphotyrosine (p-Tyr). LY294002 and rapamycin had only slight inhibitory activity, and 1-butanol did not affect phosphorylation of mTOR (Figure 4d) . In further experiments, we analyzed phosphorylation of downstream effectors of mTOR. Figure 4d shows moderate-to-high inhibition of phosphorylation of both 4E-BP1 and S6 by LY294002, wortmannin and rapamycin (Figure 4d ). Our data suggest that aberrant activation of mTOR depends on PI3K. The reason why LY294002 and wortmannin showed different ability to inhibit mTOR is unclear. A recent report demonstrated that LY294002 can also inhibit the widely expressed protein casein kinase-2 (CK-2). 40 However, our data argued against involvement of CK-2 in the DTrkA-induced transformation (data not shown). The potential role of PLD in activation of mTOR signaling was confirmed by western blot analysis showing moderate dephoshorylation of S6 protein and 4E-BP1 by 1-butanol (Figure 4d ). 1-butanol did not inhibit phosphorylation of mTOR in DTrkA-induced leukemic cells (Figure 4d ), in agreement with previous observations that neither PA nor 1-butanol had any effect on mTOR kinase activity in vitro and in vivo. 36 However, PA binding to the FKBP12-rapamycin binding (FRB) domain of mTOR may be required to allow mTOR to activate downstream pathways. 36 Taken together, our data demonstrate that the PI3K-mTOR pathway is the decisive transformation pathway, and PLD is also involved in DTrkA-mediated transformation. However, how can we explain that Akt was not constitutively phosphorylated? Akt may either not represent the predominant activator of mTORraptor in DTrkA-induced leukemia or be subject to negative feedback regulation by activation of mTOR (and/or its downstream target p70S6K), as observed in insulin signaling and tumors in TSC2 þ /À mice. 5 However, in agreement with a recently published study, 20 we did not find reactivation of Akt after treatment of rapamycin (data not shown), arguing against the latter hypothesis. Absence of constitutive activation of Akt could also be explained by the recent finding that the rapamycin-insensitive mTOR-rictor is required for fully activating Akt. 41 We do not rule out the possibility that the activation level of Akt may be very low in DTrkA-induced leukemia. In the context of tumorigenesis, it is possible that the relative contributions of each of upstream pathways to mTOR activation depend on the cell type and/or growth factors. 5 Experiments are ongoing to determine how the PI3K pathway activated mTOR in DTrkA-induced leukemia, for instance to what extent Akt contributed to activation of mTOR. In contrast to the inhibition of the rapamycin-sensitive variant, mTOR-raptor, the inhibition of PI3K almost completely abrogated growth of leukemic cells in vitro (Figure 4b) . Together with the fact that inhibition of PLD was less effective than that of mTOR (Figure 4 ), this suggests that other downstream targets of PI3K, for example the activation of PDK1, 4 may have contributed to the transformation by DTrkA. The identification of new components and novel regulatory modes in PI3K-mTOR signaling (including PLD) will facilitate the future development of diagnostic and therapeutic strategies (Figure 4e ).
HSC were targeted by DTrkA
Our data reveal that at least three types of leukemia are the consequence of DTrkA transduction in primary hematopoietic cells: AML, MPD-like myeloid leukemia and T lymphoblastic leukemia (ALL). These distinct phenotypes may reflect distinct leukemia-initiating target cells, or they arise from the same target cells (for example HSC), and pathogenic differences between the distinct DTrkA-associated leukemia phenotypes may be related to the nature of the collaborating events. Some data support the latter hypothesis: (1) transplantation of leukemic cells isolated from the early stage of disease (AML) into lethally irradiated secondary recipients did not re-induce this disease, but rather gave rise to ALL after a latency of 478 days (Supplementary data). As half of primary recipients survived the early burst of myeloid blast formation, we therefore prefer the term 'transient leukemia' (TL) for this unique phenotype. In our study, AML was diagnosed according to the criteria of the Bethesda proposals. 26 It is worth to note that transplantability per se should not serve as a defining element for mouse hematopoietic neoplasms. 26 (2) The short latency of the TL, the polyclonal nature, together with the fact that no additional genetic abnormality was found by SKY analysis, suggest that DTrkA alone is capable of inducing AML when introduced into a sufficient number of hematopoietic repopulating cells. The long latency and the presence of oligo-or monoclonal disease confirm the conclusion that DTrkA alone may be insufficient to induce these phenotypes (mainly lymphoblastic leukemia). In contrast to early AML, lymphoid leukemia induced by DTrkA was transplantable and leukemic blasts proliferated in the absence of growth factors (data not shown). Taken together, we postulate that DTrkA alone initiates a TL that is fatal in about half of the cases as a result of severe lung complications or liver damage (Figure 2) . Accordingly, the initial stage (TL) is characterized by polyclonal accumulation of blasts in the blood, BM, spleen and liver. As yet, undetermined mechanism(s), which might consist of programmed cell death, cell senescence or differentiation, allow the spontaneous resolution and extinction of TL in many cases. In these cases, however, a latent population gives rise to a clonal disorder ('later' leukemias).
To address the hypothesis that stem cells were transformed by DTrkA, we first performed FACS analysis of the stem cells in primary early AML increased mice and found that diseased animals had more than tenfold HSC than control mice, and 490% of long-term HSC were transduced by DTrkA (Supplementary data). We next expressed DTrkA in sorted HSC populations (LSK) from healthy C57Bl/6 mice and transplanted the cells in five lethally irradiated animals. Two of them died of early AML and the others developed later leukemia (lymphoblastic leukemia and mixed leukemia) (Supplementary data), thus giving a very similar kinetic as DTrkA-transduced Lin À cells (Figure 1d ). This strongly supports the hypothesis that stem cells were targeted, and gave rise to distinct phenotypes observed in our study. However, we cannot rule out the possibility that the early polyclonal AML may arise from cells other than long-term HSC, for example short-term HSC. Survival of a TL with subsequent development of clonal ALL or myeloid leukemia is reminiscent of leukemogenesis in Down syndrome neonates. 42 Approximately 10% of newborn infants with Down syndrome develop myeloid leukemia/myeloproliferative disease, which usually resolves spontaneously during the first months of life. In approximately 25% of cases that recover, AL will develop in the first 4 years of life. Focusing on TL in the present study and in Down syndrome, it will be important to define the specific genetic events that are responsible for spontaneous resolution and permanent cure and those that results in the transformation from a benign state of leukemia to an overt irreversible malignant disorder. For instance, the Bcl11 family found as a retroviral insertion site in the present study may contribute potential collaboration partners in the induction of ALL.
In summary, we for the first time investigated the leukemogenic activity of a deleted activating mutant of TRK in mouse models. DTrkA is a very potent oncogene that transforms cells via PI3K, mTOR and to some extent also PLD, without involving STAT and MAPK signaling (Figures 3 and 4) . The leukemogenic properties of DTrkA revealed in this report may have more general implications for the pathogenesis of TRK-associated cancer and the development of targeted therapy. A TRKA alternative splice product with a similar structure as DTrkA was recently identified in human neuroblastoma, and shown to promote tumorigenesis via PI3K/AKT but not RAS/MAPK signaling. 43 Reflecting with the high incidence of TRKA expression in human leukemia 12 and the recent finding that TRK receptors can also be activated in the absence of neurotrophins, 44 our data suggest an important role of altered TRK signaling in leukemogenesis. While the incidence of autonomous TRK mutants in human leukemia remains to be determined, further studies of neurotrophin receptors and downstream signaling events will certainly provide important insights into the pathogenesis of and molecular treatment options for hematological malignancies.
